PESUB26 | The first-in-human clinical trial of STP0404, a novel potent HIV-1 allosteric integrase inhibitor | Poster exhibition | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
PESUC18 | Disproportionate HIV burden among key populations in sub-Saharan Africa: national estimates of population size, HIV prevalence, and ART coverage | Poster exhibition | Surveillance of HIV in key populations |
PESUC19 | Assessing levels of provincial HIV virological suppression in the public health sector in South Africa during the COVID-19 pandemic | Poster exhibition | Monitoring and evaluation of health systems along the HIV cascade |
PESUC20 | Projection of age of people living with HIV and time since ART initiation in high-income countries in 2030: estimates for France | Poster exhibition | Modelling future healthcare needs |
PESUC21 | Life years gained with improved HIV care among non-Hispanic Black and White people who have ever injected drugs (PWID) with HIV: a modeling study | Poster exhibition | Modelling the impact of service models on the HIV epidemic |
PESUC22 | Is Thailand on track to achieve 95-95-95 targets by 2025? | Poster exhibition | Modelling the impact of service models on the HIV epidemic |
PESUC23 | Characterising the HIV care cascade in Saskatoon, Saskatchewan, 2018 - 2021 | Poster exhibition | Modelling the impact of service models on the HIV epidemic |
PESUC24 | Willingness to use PrEP among gay, bisexual, and other men who have sex with men in five Asian countries: results of the Asia Pacific MSM internet survey | Poster exhibition | Demand creation for PrEP use |
PESUC25 | Recovery in the uptake of pre-exposure prophylaxis (PrEP) in Australia after COVID-19 restrictions: analysis of national pharmacy dispensing data | Poster exhibition | Scale up of PrEP |
PESUC26 | Fostering access to PrEP among high-risk adolescent girls and young women aged 16 to 24 years through the DREAMS initiative in 4 districts in Zambia | Poster exhibition | Scale up of PrEP |